How Does Normothermic Machine Perfusion Technology Reinvent the New Paradigm of Research and Development in the Field of Organ Medicine?

Currently, the field of organ medicine is at a critical juncture for the innovation of research and development paradigms. Traditional in vitro models are overly simplified and distorted, animal experiments are costly with significant interspecies differences, and the success rate of clinical translation is low. Globally, regulatory trends are collectively driving the advancement of alternative technologies. The industry urgently needs a more human-body-relevant, quantifiable, intervenable, and reproducible organ-level in vitro research platform.

Normothermic Machine Perfusion (NMP) technology is the core underlying support for this demand. It maintains the viability and metabolic function of ex vivo organs in a near-physiological environment, transforming static tissue samples into an ex vivo living system that can be dynamically evaluated, precisely intervened upon, and operated stably over the long term.

Why is the multi-organ normothermic mechanical perfusion platform based on NMP technology gradually becoming an essential tool for research and development in the field of organ medicine?

This requires returning to the core essence of NMP technology: normothermic machine perfusion system (37°C) establishes a circulation and metabolic environment closer to physiological conditions, allowing organs to receive normal oxygen supply and maintain vascular blood flow in a circulating state. By stably maintaining the viability and complete metabolic function of ex vivo organs, it transforms ex vivo organs from "static tissues" into "metabolizable, repairable, evaluable, and intervenable" living systems.

Based on the ability to highly reproduce the in vivo microenvironment, the "living bioreactor" constructed using NMP technology bridges the gap between cells, organoids, and whole animals. It supports critical validation steps in cutting-edge fields such as cell therapy and drug screening, transitioning from laboratory to clinical applications. This makes it a core bridge connecting basic research with clinical translation and an irreplaceable central tool in organ medical research.

In the key directions of life sciences and pharmaceutical innovation, NMP, with its unique positioning in in vitro physiological-level models, provides a breakthrough path.

Break through the core bottlenecks of cell delivery, colonization, survival, and functional integration, validate repair solutions and evaluate effectiveness under controllable physiological conditions, and promote regenerative medicine to advance from cellular-level repair to organ function restoration.

Fill the "evaluation gap" between cell experiments and clinical trials, provide organ-level data closer to the human body, support key assessments such as pharmacokinetics, toxicity, targeting efficiency, and combination therapy, and significantly reduce R&D investment and clinical failure rates.

At the same time, NMP technology also has critical supporting value in cutting-edge fields such as xenotransplantation, organoids/organ-on-a-chip, and can address the shortcomings of existing models and improve the reliability of validation. Driven by both policy guidance and industry demand, NMP is upgrading from an optional technology to essential infrastructure for research institutions and innovative pharmaceutical companies.

Against the backdrop of global competition in organ medical equipment, achieving independent control of core technologies, self-sufficiency in key materials, and a fully autonomous closed-loop system has become a strategic necessity for life science research and development in China.

Beijing QingHan Medical Technology Co., Ltd., as the builder of China's NMP research system and the leader in multi-organ normothermic machine perfusion platforms, has achieved independent core technology research and development along with engineering implementation:

First, it has built a mature research-grade platform that can cover multi-organ research scenarios.Currently, it supports long-term extracorporeal perfusion of multiple organs such as the liver and kidneys, with comprehensive capabilities including pulsatile perfusion, dual circulation control, efficient oxygenation, full-process biochemical monitoring, and functional quantitative output. Its full-chain consumables include配套一次性无菌管路, dedicated oxygenators, and customized perfusate, enabling a one-stop delivery of equipment + consumables + services, which can significantly lower the usage threshold and experimental risks for research institutions in the field of organ medicine.

Secondly, it focuses on the in-depth development of membrane materials and intelligent infusion technology, with core technologies being independently controllable.Beijing QingHan Medical Technology Co., Ltd. has built an organ bionic equipment platform with independent intellectual property rights based on "Chinese membrane" through its long-term accumulation in areas such as artificial heart-lung, membrane materials, surface coatings, and microcirculatory perfusion. This breakthrough ends foreign technological monopolies, achieving self-control over key components and core processes while providing a secure, reliable, and sustainable technical foundation for national-level scientific research projects. Currently, the company is expanding into a full range of extracorporeal platforms. By mastering the production technology of the "chokepoint" membrane material PMP hollow fiber membrane and integrating intelligent algorithms based on microcirculatory perfusion, it further strengthens its technological barriers in building a multi-organ normothermic machine perfusion platform.

Thirdly, based on the deep collaboration of industry-university-research, it further promotes the landing and transformation of achievements.Currently, Beijing QingHan Medical Technology Co., Ltd. is establishing stable collaborations with top clinical institutions and research academies in China. They have completed a series of experimental validations, including perfusion model construction, organ function evaluation, stem cell delivery, and drug assessment, forming a complete closed loop from technology platforms to research solutions and from data generation to achievement transformation. More importantly, their technology not only serves basic research but will also directly support preclinical translation, demonstrating high practicality and industrialization potential.

Currently, Beijing QingHan Medical Technology Co., Ltd. has taken the lead in undertaking key scientific research projects such as the "Challenge Leader" initiative for national-level artificial intelligence medical device innovation and the Beijing Science and Technology Plan. Its technical strength has gained authoritative recognition, establishing itself as a core force supporting innovation in organ medicine.

The global organ medicine R&D is accelerating from the cellular level, animal level, towards an era of organ-level, humanized, and highly realistic in vitro models. The R&D pathways, evaluation standards, and transformation logic are being systematically reconstructed, with NMP at the core of this transformation as the key infrastructure.

Recently, at the "2026 (8th) World Conference and Exhibition on Cell Therapy and Regenerative Medicine," QingHan Medical showcased its multi-organ normothermic machine perfusion research platform to the public.QingHan Medical once again conveyed a clear concept to the industry: normothermic machine perfusion is not only a technology for organ preservation but also the underlying infrastructure supporting breakthroughs at the forefront of organ medicine.

Dr. Zuo Panli, Vice General Manager of QingHan Medical, emphasized, "The clinical application of normothermic machine perfusion technology has been confirmed globally and is currently expanding into areas such as cell therapy and drug development. The focus is on achieving longer organ preservation and enabling online measurement of more biological parameters. QingHan Medical hopes to collaborate with domestic partners in China for mutual benefit, advancing the exploration and application of domestically developed normothermic machine perfusion technology in the field of organ medicine."

Represented by QingHan Medical, China's innovative forces will further utilize the "Ex Vivo Living Bioreactor" NMP research platform to unlock more possibilities in the field of organ medicine, driving organ medical research into a new era that is more realistic, efficient, and controllable.